Clinical trials: Synucleinopathy
Parkinson's Disease, Depression
Barriers to Mental Healthcare Utilization in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder in the elderly. In most people, the illness is complicated by co-occurring psychiatric problems such as depression and anxiety.
- Conditions
- Parkinson's Disease, Depression, Anxiety
- Trial name
- NCT01167608
- Testing
- No Intervention. This is a cross-sectional survey study.
- Where
- United States
- Volunteers
- 883 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Parkinson's Disease, Deep Brain Stimulation
Dual-task Augmented Reality for PD DBS
The goal of this project is to evaluate the safety and preliminary effectiveness of utilizing a digital therapeutic, Dual-task Augmented Reality Treatment (DART) protocol, for the treatment of postural instability and gait…
- Trial name
- DART for DBS (NCT06418152)
- Testing
- Multi-modal treatment
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jay Alberts
Parkinson Disease
50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease
Background: In transcranial magnetic stimulation (TMS), a device creates a short-lasting magnetic field which induces an electric current in the brain leading to a change in the activity of brain cells.
- Trial name
- NCT00977184
- Testing
- 50 HZ Repetitive TMS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
This is an open-label, prospective post marketing surveillance study to be performed in Sweden. Only data of patients idiopathic PD should be documented, in whom the treating physician plans to initiate a pharmacotherapy with PPX…
- Trial name
- NCT01097421
- Testing
- Pramipexole Extended Release
- Volunteers
- 329 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
OpiCapone Effect on Motor Fluctuations and pAiN
The aim of this study is to investigate the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with…
- Trial name
- OCEAN (NCT04986982)
- Testing
- Opicapone 50 mg
- Where
- United Kingdom
- Volunteers
- 144 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease, Brain Stimulation
Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder and affects approximately 1 million people in the United States with total annual costs approaching 11 billion dollars.
- Conditions
- Parkinson Disease, Brain Stimulation, Cerebellum
- Trial name
- NCT04046055
- Testing
- Transcranial direct current stimulation at 2 mA, Transcranial direct current stimulation at 4 mA
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Thorsten Rudroff